HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$10.27
-0.10 (-0.96%)
▼
5d:
+1.38%
30d:
+11.39%
90d:
+3.32%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 29, 2026
4d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HLN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HLN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.87
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$8.62
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $10.27, which is considered extended relative to its 30-day fair value range of $8.95 to $9.87. The stock's valuation (Forward PE: 16.6) is in line with its historical norms (16.3). At these levels, the market is pricing in 0.6% annual earnings growth.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $10.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HLN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.93 (+16.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $10.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HLN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.93 (+16.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.95 -
$9.87
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($11.93)
- BULLISH: Expecting earnings turnaround to 0.6% growth with 2.2% revenue growth
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.95 -
$9.87
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.33
Resistance Level
$10.40
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.63
Wall Street Target
$11.93
(+16.2%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
-4.5%
Profit Margin
14.5%
Valuation Premium vs History
+0.6% premium
PE vs Historical
16.6 vs 16.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.6%
(market-implied from PE analysis)
1-Year Target
$10.33
(+1%)
2-Year Target
$10.39
(+1%)
3-Year Target
$10.46
(+2%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$10.25
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 9.3%)
$16.01
(+56%)
Base:
(SPY PE: 16.6, Growth: 9.3%)
$13.41
(+31%)
Bear:
(PE: 14.1, Growth: 9.3%)
$11.40
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 21.16 | Current EPS (TTM): $0.49
Bull Case
$14.37
(+40%)
Analyst growth 26.0%, PE expands to 23.3
Base Case
$13.07
(+27%)
Market implied 26.0%, PE stable at 21.2
Bear Case
$7.05
(-31%)
Severe decline -20.0%, PE contracts to 18.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 7:32 PM ET
Data refreshes hourly during market hours. Next update: 8:32 PM
Data refreshes hourly during market hours. Next update: 8:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
